NO2106260T3 - - Google Patents

Info

Publication number
NO2106260T3
NO2106260T3 NO08700385A NO08700385A NO2106260T3 NO 2106260 T3 NO2106260 T3 NO 2106260T3 NO 08700385 A NO08700385 A NO 08700385A NO 08700385 A NO08700385 A NO 08700385A NO 2106260 T3 NO2106260 T3 NO 2106260T3
Authority
NO
Norway
Application number
NO08700385A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007902013A external-priority patent/AU2007902013A0/en
Application filed filed Critical
Publication of NO2106260T3 publication Critical patent/NO2106260T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO08700385A 2007-01-25 2008-01-25 NO2106260T3 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89776907P 2007-01-25 2007-01-25
AU2007902013A AU2007902013A0 (en) 2007-04-17 Inhibitory compounds
US98433507P 2007-10-31 2007-10-31
US737607P 2007-12-11 2007-12-11
PCT/AU2008/000089 WO2008089521A1 (en) 2007-01-25 2008-01-25 Insulin sensitisers and methods of treatment

Publications (1)

Publication Number Publication Date
NO2106260T3 true NO2106260T3 (no) 2018-05-05

Family

ID=39644028

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08700385A NO2106260T3 (no) 2007-01-25 2008-01-25

Country Status (12)

Country Link
US (3) US8455432B2 (no)
EP (1) EP2106260B8 (no)
JP (1) JP5301465B2 (no)
CN (1) CN101801375B (no)
AU (1) AU2008209320B2 (no)
CA (1) CA2676051C (no)
ES (1) ES2660170T3 (no)
NO (1) NO2106260T3 (no)
NZ (1) NZ579229A (no)
PL (1) PL2106260T3 (no)
PT (1) PT2106260T (no)
WO (1) WO2008089521A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5301465B2 (ja) 2007-01-25 2013-09-25 バーバ・ファーマシューティカルズ・リミテッド インスリン抵抗性改善薬および治療方法
US20200155558A1 (en) * 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BR112014029308A2 (pt) * 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática
EP2854806A4 (en) * 2012-05-24 2015-11-18 Verva Pharmaceuticals Ltd METHOD OF WEIGHT REDUCTION
AU2013202988B2 (en) * 2012-06-29 2016-04-21 NAIA Metabolic, Inc. Method of improving liver function
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) 1957-02-26 S-acylimino-x-substituted-az-i
US2994701A (en) 1961-08-01 Z-sulfamyr
US2554816A (en) 1950-04-04 1951-05-29 American Cyanamid Co Heterocyclic sulfonamides and methods of preparation thereof
GB795174A (en) 1954-10-13 1958-05-21 Upjohn Co Heterocyclic sulphonamides
US2835702A (en) 1956-05-02 1958-05-20 Merck & Co Inc Benzene 1, 3 disulfonamides possessing diuretic properties
US2978457A (en) 1959-04-06 1961-04-04 Merck & Co Inc 5-acylamido-4-substituted-thiazole-2-sulfonamides having diuretic properties
US3157572A (en) 1961-01-06 1964-11-17 American Cyanamid Co Parenteral diuretic compositions of 5-acylimino-4-substituted-delta2-1, 3, 4-thiadiazolidine-2-sulfonamides
US3668248A (en) 1964-09-30 1972-06-06 Lilly Co Eli 5-chloro-2,4-bis(sulfamoyl)fluorobenzene and 5-chloro-2,4-bis(chlorosulfonyl)fluorobenzene
FR2468366A1 (fr) 1979-10-31 1981-05-08 Stoclet Alain Medicament antiglaucomateux a base d'acetazolamide ou de methazolamide
EP0096003B2 (de) 1982-05-28 1994-06-15 Ciba-Geigy Ag Neue Sulfonyl(thio)harnstoffe, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und/oder Wachstumsregulatoren
IT1224860B (it) 1988-07-29 1990-10-24 Istituto Chimico Internazional Composti correlati all'acetozolammi de con attivita' inibitrice dell'anidrasi carbonica, utili in particolare nel trattamento del glaucoma
GB2223166B (en) 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
US5585377A (en) 1990-04-09 1996-12-17 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5153192A (en) 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors
US5378703A (en) 1990-04-09 1995-01-03 Alcon Laboratories, Inc. Sulfonamides useful as carbonic anhydrase inhibitors
US5225424A (en) 1992-10-21 1993-07-06 University Of Iowa Research Foundation Methazolamide-derived carbonic anhydrase inhibitors
US5519040A (en) 1994-04-29 1996-05-21 Allergan Substituted thiazole sulfonamides as antiglaucoma agents
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5723476A (en) 1995-11-17 1998-03-03 Pharmacia & Upjohn Company 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus
JP2000080047A (ja) 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
GB9930688D0 (en) * 1999-12-24 2000-02-16 Smithkline Beecham Plc Novel method of treatment
JP2003518493A (ja) 1999-12-24 2003-06-10 スミスクライン ビーチャム パブリック リミテッド カンパニー 新規治療方法
DK1309324T3 (da) * 2000-07-07 2006-06-12 Ortho Mcneil Pharm Inc Antikonvulsive derivater egnede til behandling og forebyggelse af udvikling af type II diabetes mellitus og syndrom X
US6946243B2 (en) 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
DE10035227A1 (de) 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
DE10038022A1 (de) 2000-08-04 2002-02-14 Bayer Ag Inverse Thiazolylamid-Derivate
EP1307185B1 (en) 2000-08-11 2005-04-13 Einar Stefansson Use of carboanhydrase inhibitors for the prevention of diabetic retinopathy in diabetics
FR2816841B1 (fr) 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
DE60108173T2 (de) 2000-12-22 2005-06-02 Dow Global Technologies, Inc., Midland Propylencopolymerschäume
EP1695716A2 (en) 2000-12-26 2006-08-30 Sankyo Company, Limited Medicinal compositions containing diuretics and insulin sensitizers
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2003294376A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
JP2006520335A (ja) 2003-03-18 2006-09-07 ノバルティス アクチエンゲゼルシャフト 脂肪酸とアミノ酸を含有する組成物
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
TW200526678A (en) 2003-08-01 2005-08-16 Janssen Pharmaceutica Nv Substituted indole-O-glucosides
ATE551997T1 (de) * 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes
TW200533336A (en) 2004-03-02 2005-10-16 Fujisawa Pharmaceutical Co Concomitant drugs
WO2005110413A2 (en) 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Medicaments containing n-sulfamoyl-n'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US7670794B2 (en) 2005-11-04 2010-03-02 Washington University Managing glycemia status in diabetic patients
US20070110707A1 (en) * 2005-11-04 2007-05-17 Washington University Method of treating diseases involving non-enzymatic glycation
ZA200803809B (en) 2005-11-14 2009-10-28 Solvay Pharm Gmbh N-sulfamoyl-N'-benzopyranpiperidines as inhibitors of carbonic anhydrases
AR057570A1 (es) 2005-11-14 2007-12-05 Solvay Pharm Gmbh Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o
WO2007065948A1 (en) 2005-12-09 2007-06-14 Solvay Pharmaceuticals Gmbh Novel n-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
WO2007114948A2 (en) 2006-04-04 2007-10-11 The Brigham And Women's Hospital, Inc. Methods and compositions for inhibiting cell death
JP5301465B2 (ja) * 2007-01-25 2013-09-25 バーバ・ファーマシューティカルズ・リミテッド インスリン抵抗性改善薬および治療方法
JPWO2011002011A1 (ja) 2009-07-01 2012-12-13 キッセイ薬品工業株式会社 Ｓｇｌｔ１阻害薬とｄｐｐ−ｉｖ阻害薬を組み合わせてなる医薬
DK3459558T3 (da) 2010-06-25 2020-11-02 Univ Aston Glycoproteiner med lipidmobiliserende egenskaber og terapeutiske anvendelser deraf
JP5722892B2 (ja) 2010-07-15 2015-05-27 武田薬品工業株式会社 複素環化合物
EP2854806A4 (en) 2012-05-24 2015-11-18 Verva Pharmaceuticals Ltd METHOD OF WEIGHT REDUCTION
BR112014029308A2 (pt) 2012-05-24 2017-06-27 Verva Pharmaceuticals Ltd um método de melhorar a função hepática

Also Published As

Publication number Publication date
CN101801375B (zh) 2014-01-01
US10172837B2 (en) 2019-01-08
EP2106260B8 (en) 2018-04-04
CA2676051C (en) 2017-06-06
US20110003740A1 (en) 2011-01-06
JP2010516711A (ja) 2010-05-20
US20170079960A1 (en) 2017-03-23
US20140011848A1 (en) 2014-01-09
CA2676051A1 (en) 2008-07-31
PL2106260T3 (pl) 2018-06-29
AU2008209320B2 (en) 2013-05-30
EP2106260A4 (en) 2010-05-26
JP5301465B2 (ja) 2013-09-25
CN101801375A (zh) 2010-08-11
US8455432B2 (en) 2013-06-04
US9452148B2 (en) 2016-09-27
WO2008089521A1 (en) 2008-07-31
EP2106260B1 (en) 2017-12-06
NZ579229A (en) 2011-07-29
PT2106260T (pt) 2018-03-05
AU2008209320A1 (en) 2008-07-31
EP2106260A1 (en) 2009-10-07
ES2660170T3 (es) 2018-03-21

Similar Documents

Publication Publication Date Title
NO2106260T3 (no)
CN300731448S (zh) 床架
CN300729244S (zh) 手锯(bt316b)
CN300809765S (zh) 电脑cpu散热装置(1)
CN300808650S (zh) 学生衣柜(f3131e)
CN300792410S (zh) 梳妆台(1)
CN300789841S (zh) 曲线锯
CN300770554S (zh) 瓷砖(t-003)
CN300728159S (zh) 适配器(2)
CN300770262S (zh) 烟花(盆状 孔雀开屏)
CN300731681S (zh) 纯银保健杯(龙行天下)
CN300833960S (zh) 包装盒(侬侬橙汁)
CN300731431S (zh) 椅(4)
CN300731301S (zh) 面料(zj-xmas04)
CN300731273S (zh) 面料(艺术染整2007-03)
CN300731272S (zh) 面料(艺术染整2007-42a)
CN300731253S (zh) 面料(艺术染整2007-43)
CN300730921S (zh) 大灯
CN300730899S (zh) 夜灯外壳
CN300728260S (zh) 骨科电磁式冲击波治疗机
CN300730839S (zh) 蜡烛(111)
CN300730837S (zh) 蜡烛(103)
CN300730815S (zh) 蜡烛(106)
CN300730787S (zh) 蜡烛(130)
CN300730731S (zh) 手电筒(tf-b)